Abstract: The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication agent, or in combinations thereof. Described are soft gelatin capsules characterized by improved stability as compared with gelatin capsules that do not contain amino acid in the shell and carboxylic acid ester in the filling, shell or in the lubrication agent, or in combinations thereof.

Abstract: The present invention describes soft gelatin capsules that encapsulate a water-insoluble active ingredient and an excipient composed of a crystallization inhibitor that stabilizes the water-insoluble inhibitor. The crystallization inhibitor being at least one mononacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbon atoms. The capsule contents are more resistant to turbidity, forming a coarse emulsion, and crystallization of the active ingredient compared with compositions absent the crystallization inhibitor.

Abstract: Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties.

Abstract: A method of increasing viscosity of a pharmaceutical formulation for oral or topical administration comprises the steps of combining: a. an effective amount of one or more hydrophobic active ingredients; b. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids of formula (1) CH2OR—CHOR—CH20-[CH2CHOR—CH2O—]NCH2—CHOR—CH2OR??(1) wherein n is an integer from 4 to 13 and R is H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen; c. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2) CH2OR—CHOR—CH20-[CH2CHOR—CH2O]NCH2—CHOR—CH2OR??(2) wherein n is an integer from 0 to 10 and R?H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen; d.

Abstract: Pharmaceutical compositions especially for internal application which create lyotropic liquid crystals when in contact with aqueous phase. The pharmaceutical compositions consist of: A hydrophobic active ingredient with immunomodulatory effect from a group of N-methylated cyclic undecapeptides or macrolide antibiotics, in quantity 1-35 weight % in a carrier medium containing B at least one absorption promoter allowing for contact of the drug with a biological membrane or passing of the drug through in quantity 1-40 weight %, C nonlipidic vehicle containing at lest one of the below mentioned substances: C1 surfactant or mixed surfactant with HLB>9, in quantity 1-80 weight % C2 lipophilic solvent from group of higher fatty alcohols in quantity 1-30 weight % C3 at least one cosurfactant in quantity 1-50 weight %, while a ratio among the individual components of the product is A:B:C=1:0.5-4:5-8.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Therapeutical compositions comprising from 0.1 to 20% by weight of a cyclosporin and a vehicle comprising from 1 to 60% by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide, and from 1 to 60% by weight of a mixture of glyceryl monoesters of C.sub.8 -C.sub.22 fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C.sub.8 -C.sub.22 fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilizers, flavoring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.